Nuformix PLC Directorate Change (7810L)
10 Septiembre 2019 - 1:02AM
UK Regulatory
TIDMNFX
RNS Number : 7810L
Nuformix PLC
10 September 2019
10th September 2019
Nuformix plc
("Nuformix" or "the Group"),
Resignation of Kirk Siderman-Wolter
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs announces the resignation of Kirk Siderman-Wolter
from the Nuformix Board of Directors with immediate effect. The
resolution to re-elect Kirk Siderman-Wolter as a Director of the
Company at the Annual General Meeting to be held at 1pm today will
now be withdrawn from the meeting.
Dr Dan Gooding, CEO, Nuformix plc, said: "On behalf of the Board
and the Company, I would like to thank Kirk for his work and
commitment to the Board and the Company during his tenure, a period
of tremendous growth and change for the Company. The Board would
like to wish Kirk well in his future endeavours."
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 627222
Optimum Strategic Communications
Mary Clark, Supriya Mathur +44 (0) 20 3950
Email: nuformix@optimumcomms.com 9144
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix's IP portfolio of granted patents covers cocrystal
forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALMMATMBIBMFL
(END) Dow Jones Newswires
September 10, 2019 02:02 ET (06:02 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024